Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Download White Paper
IT in
Healthcare,
Patient
Monitoring &
Telemedicine

Download White Paper

 
Matching geography
Reports matching your search in:
 
 
Download SlideShare
20
Hot
Stats on
Healthcare
IT

Download SlideShare

 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Parkinson's Disease: market research reports

1594
A disease of the motor system, generally, PD affects people over the age of 50. Early symptoms of PD are subtle and occur gradually. In some people the disease progresses more quickly than in others. Symptoms of Parkinson’s Disease would be tremor in body or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; slowness of movement or impaired balance and coordination.
These are very visible symptoms, and patients may have difficulty walking, talking, or completing other simple tasks.

As the disease progresses, the shaking, or tremor, which affects the majority of PD patients may begin to interfere with daily activities. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD. Therefore the diagnosis is based on medical history and a neurological examination. The disease can be difficult to diagnose accurately.

There is no cure for PD, but a variety of medications provide dramatic relief from the symptoms. Usually, patients are given levodopa combined with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Anticholinergics may help control tremor and rigidity. Other drugs, such as bromocriptine, pramipexole, and ropinirole, mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine. An antiviral drug, amantadine, also appears to reduce symptoms.

RSS Feeds

Parkinson's Disease market research reports and industry analysis

< prev 1  2  3  next >
Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff
3/20/2013 | published by: GBI Research
... research “Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in ...  |  read more...
$3,500.00
Parkinson's Disease – Pipeline Review, H1 2013
2/28/2013 | published by: Global Markets Direct
... Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. Parkinson's Disease - Pipeline Review, Half Year is ...  |  read more...
$2,000.00
Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017
1/16/2013 | published by: MarketsandMarkets
... a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain ...  |  read more...
$4,650.00
Neurostimulation Devices Market, 2012-2017
11/5/2012 | published by: Banyan Wharf Consultants Ltd.
... mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS). The market is still niche, with limited number of devices available in the market. The ...  |  read more...
$1,699.00
Parkinson's Disease Global Clinical Trials Review, H2, 2012
10/31/2012 | published by: GlobalData
... and data relating to the clinical trials on Parkinson’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  read more...
$2,500.00
Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments
9/19/2012 | published by: Kalorama Information
... emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) ...  |  read more...
$1,500.00
Analyzing the Global CNS Market
9/1/2012 | published by: Aruvian's R'search
... development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, ...  |  read more...
$650.00
Market and Product Forecasts: Top 10 Neurology Brands 2011–21
9/1/2012 | published by: Datamonitor
... and the pitfalls of R&D can insulate brands from competition. The neurology market is set to remain an attractive long-term prospect. Neurology brands were worth a combined $30.6bn in the seven major markets in 2011, ...  |  read more...
$11,400.00
Global Markets for Treatments of Dementia and Movement Disorders - Focus on Movement Disorders
9/1/2012 | published by: BCC Research
... in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%. Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of ...  |  read more...
$4,400.00
Parkinson's Disease
8/9/2012 | published by: Decision Resources
... of polypharmacy that is unique among neurological disorders, driven by the need to manage primary motor symptoms and nonmotor symptoms of the disease as well as the need to manage complications associated with levodopa (multiple ...  |  read more...
$15,000.00
The Neurotechnology Industry 2012 Report
8/1/2012 | published by: NeuroInsights, LLC
... comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets. The report includes detailed information on ...  |  read more...
$4,500.00
Disease and Therapy Review: Parkinson's Disease
6/28/2012 | published by: Timely Data Resources, Inc.
... diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the Parkinson's Disease market, as well as sales of leading drugs and therapies are provided.  |  read more...
$995.00
R&D Trends: Parkinson's Disease – Pipeline swells but a paradigm shift is unlikely in the mid-term
6/15/2012 | published by: Datamonitor
... Impax/GSK’s IPX066 for idiopathic Parkinson’s disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy. Features and benefits Understand key dynamics in the R&D pipeline for new Parkinson’s disease ...  |  read more...
$3,800.00
Neuroprotective Products: World Market Prospects 2012-2022
5/10/2012 | published by: Visiongain
... projected sales at overall world market, therapeutic submarket and product level to 2022. The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding ...  |  read more...
$2,739.00
Epidemiology: Parkinson’s Disease – Aging population drives up prevalence
4/4/2012 | published by: Datamonitor
... in the US. Incidence rates are expected to remain constant, while total prevalence rates will increase as a result of the aging population in the seven major markets. Introduction Gain insight into market potential, including ...  |  read more...
$5,700.00
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
1/31/2012 | published by: GlobalData
... The report is an essential source of information and analysis on the global Parkinson’s Disease (PD) therapeutics market. It provides comprehensive market information, highlighting the treatment guidelines and identifying and analyzing the key trends shaping ...  |  read more...
$6,995.00
Parkinson's Disease - Pipeline Review, H1 2012
1/23/2012 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, H1 2012' ...  |  read more...
$500.00
Parkinson's Disease Global Clinical Trials Review, H2, 2011
10/30/2011 | published by: GlobalData
... and data relating to the clinical trials on Parkinson’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  read more...
$1,000.00
Parkinson's Disease: World Drug Market 2011-2021
9/26/2011 | published by: Visiongain
... world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions. Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can ...  |  read more...
$2,739.00
Parkinson's Disease - Pipeline Review, Q3 2011
7/31/2011 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, Q3 2011' ...  |  read more...
$500.00
The 10th International Conference on Alzheimer's and Parkinson's Diseases: Post-Conference Review and Analysis
3/31/2011 | published by: GlobalData
... conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques. The annual meeting of the 10th International Conference on Alzheimer’s and Parkinson’s Diseases was held in ...  |  read more...
$1,000.00
The Michael J. Fox Foundation for Parkinson's Research-Detailed Product Pipeline
3/14/2011 | published by: Life Science Analytics (LSA)
... reports Accessing accurate, current and comprehensive content on global public and private pipeline companies can be challenging however, Life Science Analytics has created a suite of reports that deliver the latest information on over 2,500 ...  |  read more...
$750.00
Parkinson Disease Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...  |  read more...
$1,495.00
The Michael J. Fox Foundation for Parkinson's Research-Deals & Alliances Report
3/14/2011 | published by: Life Science Analytics (LSA)
... stage of development, list of partners, deal types (licensing, marketing, etc.), top deals by deal value, partners based on technology with detailed descriptions of the partner firm where disclosed, partners based on product with detailed ...  |  read more...
$600.00
Novel Targeted Therapies Hold the Promise of Cure for Parkinson's Disease (PD)
2/28/2011 | published by: GlobalData
... of Parkinson’s Disease and how the novel pipeline molecules will drive the global market Scope Data and information on noval therapy on Parkinson’s Disease market Reasons to buy Develop business strategies by understanding the trends ...  |  read more...
$500.00
< prev 1  2  3  next >